Search results
Results From The WOW.Com Content Network
Shares of Moderna soared around 14% on Thursday on the news that a personalized cancer vaccine, produced in partnership with Merck, reduced the risk of late-stage melanoma by 49%.
Merck reported first-quarter profit of $2.07 per share on an adjusted basis, compared with analysts estimates of $1.88 per share, according to LSEG data. Sales came in at $15.8 billion, rising 9% ...
Furthermore, the company is partnering with pharmaceutical giant Merck to develop a personalized cancer vaccine, mRNA-4157. In a phase 2 study, this candidate, in combination with Merck's cancer ...
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody -based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle ), is the industry leader in antibody-drug conjugates or ADCs ...
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle ...
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical ...
The biotech is developing this potential cancer vaccine in collaboration with the pharmaceutical giant Merck, and could hardly have found a better partner for this project. Merck is one of the ...
Merck Serono (EMD Serono in the United States and Canada) is a pharmaceutical company headquartered in Darmstadt, Germany, and a brand and division of Merck focused on biopharmaceuticals. [1] In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family.